At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Peginterferon Lambda-1a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19
In Brief
A Phase 2 clinical trial evaluating Peginterferon Lambda-1a and Placebo for COVID-19. Completed, enrolled 120 participants across 1 site.
Detailed Summary
To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartApr 2020
Primary CompletionAug 2020
Study CompletionMay 2021
TodayJul 2026
First PostedApr 2, 2020
Enrollment StartApr 25, 2020
Primary CompletionAug 14, 2020
Study CompletionMay 6, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.3 years ago
Interventions
Peginterferon Lambda-1adrug
Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care
Placeboother
Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection